Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye rosacea study seeks safer antibiotic use

NCT ID NCT05296837

Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 21, 2026 · Updated 5 times

Summary

This study looks at how different doses of the antibiotic doxycycline affect antibiotic resistance in people with ocular rosacea, an inflammatory eye condition. Researchers will compare a low anti-inflammatory dose (40 mg daily) with a standard antibiotic dose (200 mg daily) and a placebo. The goal is to see which dose causes the least resistance in gut bacteria, helping guide safer long-term treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxycycline
What this could lead to
If successful, this study could help doctors choose the safest doxycycline dose for ocular rosacea, reducing the risk of antibiotic resistance.
What could go wrong
This is a small, early-phase study focused on measuring resistance, not on treating symptoms. Results may not change current practice directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

46 people

The number who actually took part.

Started

Jun 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have symptomatic ocular disease attributed to ocular rosacea as the primary diagnosis * Ability to give informed consent * Be aged 18 years old or older Exclusion Criteria: * Have an active ocular or systemic infection * Have a known allergy or intolerance to tetracycline antibiotics * Have had prior use of oral antibiotics within the last three months * Pregnancy or the possibility of becoming pregnant within the 8-week study medication timeline.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antimicrobial resistance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rosacea rosacea conjunctivitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antimicrobial resistance Ocular rosacea

Contacts and locations

Locations

  • University of California, San Farncisco

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.